KR101879887B1 - 항바이러스 치료용 2'-플루오로 치환된 카바-누클레오시드 유사체 - Google Patents
항바이러스 치료용 2'-플루오로 치환된 카바-누클레오시드 유사체 Download PDFInfo
- Publication number
- KR101879887B1 KR101879887B1 KR1020137010012A KR20137010012A KR101879887B1 KR 101879887 B1 KR101879887 B1 KR 101879887B1 KR 1020137010012 A KR1020137010012 A KR 1020137010012A KR 20137010012 A KR20137010012 A KR 20137010012A KR 101879887 B1 KR101879887 B1 KR 101879887B1
- Authority
- KR
- South Korea
- Prior art keywords
- another aspect
- compound
- alkyl
- methyl
- independently
- Prior art date
Links
- 0 CC(CO*)(C1(*)*)O[C@@](*CN2N=C(*)N[C@](*)C2=NC=*)[C@]1(*)F Chemical compound CC(CO*)(C1(*)*)O[C@@](*CN2N=C(*)N[C@](*)C2=NC=*)[C@]1(*)F 0.000 description 6
- FRYFRYYHEAGZPR-KEVCPQAKSA-N CC(C)(CO)C(SCCOP(NCc1ccccc1)(OC[C@H]([C@H]([C@@]1(C)F)O)O[C@]1(c1ccc2[n]1ncnc2N)C#N)=O)=O Chemical compound CC(C)(CO)C(SCCOP(NCc1ccccc1)(OC[C@H]([C@H]([C@@]1(C)F)O)O[C@]1(c1ccc2[n]1ncnc2N)C#N)=O)=O FRYFRYYHEAGZPR-KEVCPQAKSA-N 0.000 description 1
- UIWUAEHTKMQCBD-HKGZMVSPSA-N CC(C)OC(OCOP(OC[C@H]([C@H]([C@]1([C@@H]2C1)F)O)O[C@]2(c1ccc2[n]1ncnc2N)C#N)(OCOC(OC(C)C)=O)=O)=O Chemical compound CC(C)OC(OCOP(OC[C@H]([C@H]([C@]1([C@@H]2C1)F)O)O[C@]2(c1ccc2[n]1ncnc2N)C#N)(OCOC(OC(C)C)=O)=O)=O UIWUAEHTKMQCBD-HKGZMVSPSA-N 0.000 description 1
- RSWVSLFFXWDYAM-NIRFDDNYSA-N CCOC(C(C)(C)NP(OC[C@H]([C@H]([C@@]1(C)F)OC(C(C)C)=O)O[C@H]1c1cnc2[n]1ncnc2N)(Oc1ccccc1)=O)=O Chemical compound CCOC(C(C)(C)NP(OC[C@H]([C@H]([C@@]1(C)F)OC(C(C)C)=O)O[C@H]1c1cnc2[n]1ncnc2N)(Oc1ccccc1)=O)=O RSWVSLFFXWDYAM-NIRFDDNYSA-N 0.000 description 1
- RQRDALWOZXIEDW-VIOOABJFSA-N C[C@@H](C(OCC(C)(C)C)=O)NP(O)(OC[C@H](C[C@@]1(C)F)O[C@H]1c1cnc2[n]1ncnc2N)=O Chemical compound C[C@@H](C(OCC(C)(C)C)=O)NP(O)(OC[C@H](C[C@@]1(C)F)O[C@H]1c1cnc2[n]1ncnc2N)=O RQRDALWOZXIEDW-VIOOABJFSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/885,917 US7973013B2 (en) | 2009-09-21 | 2010-09-20 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| US12/885,917 | 2010-09-20 | ||
| US13/050,820 US8455451B2 (en) | 2009-09-21 | 2011-03-17 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| US13/050,820 | 2011-03-17 | ||
| PCT/US2011/029441 WO2012039791A1 (fr) | 2010-09-20 | 2011-03-22 | Analogues carbanucléosidiques 2'-fluoro-substitués pour traitement antiviral |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20130110168A KR20130110168A (ko) | 2013-10-08 |
| KR101879887B1 true KR101879887B1 (ko) | 2018-07-18 |
Family
ID=47748238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137010012A KR101879887B1 (ko) | 2010-09-20 | 2011-03-22 | 항바이러스 치료용 2'-플루오로 치환된 카바-누클레오시드 유사체 |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP2619206A1 (fr) |
| JP (4) | JP2013538230A (fr) |
| KR (1) | KR101879887B1 (fr) |
| CN (1) | CN103108876A (fr) |
| AP (1) | AP3699A (fr) |
| AU (1) | AU2011306066B2 (fr) |
| BR (1) | BR112013008017A2 (fr) |
| CA (1) | CA2807496C (fr) |
| CL (1) | CL2013000727A1 (fr) |
| CO (1) | CO6680669A2 (fr) |
| CR (1) | CR20130172A (fr) |
| EA (1) | EA026523B1 (fr) |
| EC (1) | ECSP13012560A (fr) |
| IL (1) | IL225221A0 (fr) |
| MA (1) | MA34593B1 (fr) |
| MX (1) | MX2013003179A (fr) |
| NZ (1) | NZ608070A (fr) |
| PE (3) | PE20230684A1 (fr) |
| SG (1) | SG188223A1 (fr) |
| WO (1) | WO2012039791A1 (fr) |
| ZA (1) | ZA201301042B (fr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2280973E (pt) | 2008-04-23 | 2013-02-04 | Gilead Sciences Inc | Análogos de carba-nucleósido para tratamento antiviral |
| CA2773773C (fr) | 2009-09-21 | 2019-04-23 | Gilead Sciences, Inc. | Procedes et intermediaires pour preparer des analogues de carba-nucleoside 1'-substitues |
| BR112013001267A2 (pt) | 2010-07-19 | 2016-05-17 | Gilead Sciences Inc | métodos para a preparação de pró-fármacos de fosforamidato diasteromericamente puro |
| SG186830A1 (en) | 2010-07-22 | 2013-02-28 | Gilead Sciences Inc | Methods and compounds for treating paramyxoviridae virus infections |
| TW201701876A (zh) | 2010-12-20 | 2017-01-16 | 吉李德科學股份有限公司 | 治療ｃ型肝炎病毒（ｈｃｖ）之方法 |
| WO2013039920A1 (fr) | 2011-09-12 | 2013-03-21 | Idenix Pharmaceuticals, Inc. | Composés de carbonyloxyméthylphosphoramidate substitué et compositions pharmaceutiques servant à traiter les infections virales |
| CN104244945B (zh) | 2011-09-16 | 2016-08-31 | 吉利德制药有限责任公司 | 用于治疗hcv的方法 |
| DK2950786T3 (da) | 2013-01-31 | 2020-02-17 | Gilead Pharmasset Llc | Kombinationsformulering af to antivirale forbindelser |
| UA119050C2 (uk) * | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
| TWI678369B (zh) * | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類 |
| CN104230985B (zh) * | 2014-09-01 | 2017-01-18 | 北京天弘天达医药科技有限公司 | (s)‑2‑[(s)‑(4‑硝基‑苯氧基)‑苯氧基‑磷酰基氨基]丙酸异丙酯的制备方法 |
| TWI687432B (zh) | 2014-10-29 | 2020-03-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| ES2892123T3 (es) | 2014-12-26 | 2022-02-02 | Univ Emory | Derivados antivíricos de N4-hidroxicitidina |
| LT3785717T (lt) | 2015-09-16 | 2022-04-11 | Gilead Sciences, Inc. | Coronaviridae infekcijų gydymo būdai |
| US10682368B2 (en) | 2017-03-14 | 2020-06-16 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
| AU2018262501B2 (en) | 2017-05-01 | 2020-12-10 | Gilead Sciences, Inc. | Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| CN111093627B (zh) | 2017-07-11 | 2024-03-08 | 吉利德科学公司 | 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物 |
| GB2581936B (en) | 2017-12-07 | 2021-02-10 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| TWI789695B (zh) | 2020-01-27 | 2023-01-11 | 美商基利科學股份有限公司 | 治療sars cov-2感染之方法 |
| AU2021234308C1 (en) | 2020-03-12 | 2024-02-22 | Gilead Sciences, Inc. | Methods of preparing 1'-cyano nucleosides |
| WO2021207049A1 (fr) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Formulations d'inhalation d'analogues de carbanucléosides à substitution 1'-cyano |
| TW202203941A (zh) | 2020-05-29 | 2022-02-01 | 美商基利科學股份有限公司 | 瑞德西韋之治療方法 |
| CN115996928A (zh) | 2020-06-24 | 2023-04-21 | 吉利德科学公司 | 1’-氰基核苷类似物及其用途 |
| TW202233204A (zh) | 2020-08-27 | 2022-09-01 | 美商基利科學股份有限公司 | 用於治療病毒感染之化合物及方法 |
| WO2023167944A1 (fr) | 2022-03-02 | 2023-09-07 | Gilead Sciences, Inc. | Composés et méthodes pour traiter des infections virales |
| WO2023207942A1 (fr) * | 2022-04-25 | 2023-11-02 | 北京沐华生物科技有限责任公司 | Médicament nucléosidique pour le traitement ou la prévention d'une infection à coronavirus, et son utilisation |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009132123A1 (fr) * | 2008-04-23 | 2009-10-29 | Gilead Sciences, Inc. | Analogues de carba-nucléoside pour un traitement antiviral |
| KR20120102605A (ko) * | 2009-09-21 | 2012-09-18 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 치료용 ２'―플루오로 치환된 카바-뉴클레오사이드 유사체 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| WO1991019721A1 (fr) | 1990-06-13 | 1991-12-26 | Arnold Glazier | Promedicaments phosphoreux |
| DK0481214T3 (da) | 1990-09-14 | 1999-02-22 | Acad Of Science Czech Republic | Prolægemidler af phosphonater |
| US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
| DE19912636A1 (de) | 1999-03-20 | 2000-09-21 | Aventis Cropscience Gmbh | Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel |
| US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
| KR20030005197A (ko) | 2000-02-18 | 2003-01-17 | 샤이어 바이오켐 인코포레이티드 | 뉴클레오시드유도체를 이용한 플라비바이러스 감염의 치료또는 예방 방법 |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| CN1646141B (zh) | 2000-10-18 | 2014-06-25 | 吉利德制药有限责任公司 | 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物 |
| MXPA03006514A (es) * | 2001-01-22 | 2004-12-02 | Merck & Co Inc | Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico. |
| WO2003026675A1 (fr) | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Procedes et compositions pour traiter des flavivirus et des pestivirus au moyen d'un nucleoside modifie en position 4' |
| KR20050088079A (ko) | 2002-11-15 | 2005-09-01 | 이데닉스 (케이만) 리미티드 | 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이 |
| CA2734052A1 (fr) * | 2003-05-30 | 2005-01-13 | Pharmasset, Inc. | Analogues de nucleosides fluores modifies |
| RU2433124C2 (ru) | 2004-09-14 | 2011-11-10 | Фармассет, Инк. | Способ получения 2'-фтор-2'-алкилзамещенных или других замещенных рибофуранозилпиримидинов и пуринов и их производных |
| US20080280842A1 (en) * | 2004-10-21 | 2008-11-13 | Merck & Co., Inc. | Fluorinated Pyrrolo[2,3-D]Pyrimidine Nucleosides for the Treatment of Rna-Dependent Rna Viral Infection |
| CN101043893A (zh) * | 2004-10-21 | 2007-09-26 | 默克公司 | 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷 |
| WO2006121820A1 (fr) | 2005-05-05 | 2006-11-16 | Valeant Research & Development | Promedicaments de phosphoramidate pour traitement d'infections virales |
| WO2007027248A2 (fr) | 2005-05-16 | 2007-03-08 | Valeant Research & Development | Analogues de nucleoside cyclique 3', 5' pour le traitement du virus de l'hepatite c (vhc) |
| WO2007056170A2 (fr) | 2005-11-02 | 2007-05-18 | Bayer Healthcare Ag | Derives pyrrolo-[2,1-f]-[1,2,4]-triazin-4-ylamines inhibiteurs de la igf-1r kinase pour le traitement des cancers et autres maladies hyperproliferatives |
| US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
| EP2124555B1 (fr) | 2007-01-05 | 2015-07-08 | Merck Sharp & Dohme Corp. | Phosphoramidates d'aryle nucléosidiques destinés au traitement de l'infection virale d'arn arn dépendante |
| CA2674589A1 (fr) | 2007-01-12 | 2008-07-24 | Biocryst Pharmaceuticals, Inc. | Analogues de nucleosides antiviraux |
| JP2010522241A (ja) | 2007-03-21 | 2010-07-01 | ブリストル−マイヤーズ スクイブ カンパニー | 増殖性疾患、アレルギー性疾患、自己免疫疾患または炎症性疾患として有用な縮合ヘテロ環化合物 |
| ES2393038T3 (es) | 2007-05-10 | 2012-12-18 | Biocryst Pharmaceuticals, Inc. | Compuestos de tretrahidrofuro[3,4-D]dioxolano para su utlilización en el tratamiento de las infecciones víricas y del cáncer |
| WO2010036407A2 (fr) * | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Analogues nucléosidiques antiviraux |
| WO2010002877A2 (fr) * | 2008-07-03 | 2010-01-07 | Biota Scientific Management | Nucléosides bicycliques et nucléotides convenant comme agents thérapeutiques |
| EA025085B1 (ru) * | 2009-02-10 | 2016-11-30 | Джилид Сайэнс, Инк. | Карбануклеозидные аналоги для противовирусного лечения |
-
2011
- 2011-03-22 SG SG2013011325A patent/SG188223A1/en unknown
- 2011-03-22 EA EA201390141A patent/EA026523B1/ru unknown
- 2011-03-22 KR KR1020137010012A patent/KR101879887B1/ko active IP Right Grant
- 2011-03-22 EP EP11715792.5A patent/EP2619206A1/fr not_active Withdrawn
- 2011-03-22 AU AU2011306066A patent/AU2011306066B2/en active Active
- 2011-03-22 CN CN2011800449231A patent/CN103108876A/zh active Pending
- 2011-03-22 PE PE2022003082A patent/PE20230684A1/es unknown
- 2011-03-22 MX MX2013003179A patent/MX2013003179A/es not_active Application Discontinuation
- 2011-03-22 JP JP2013529139A patent/JP2013538230A/ja not_active Withdrawn
- 2011-03-22 WO PCT/US2011/029441 patent/WO2012039791A1/fr active Application Filing
- 2011-03-22 CA CA2807496A patent/CA2807496C/fr active Active
- 2011-03-22 PE PE2013000530A patent/PE20131165A1/es active IP Right Grant
- 2011-03-22 BR BR112013008017A patent/BR112013008017A2/pt not_active Application Discontinuation
- 2011-03-22 NZ NZ608070A patent/NZ608070A/en unknown
- 2011-03-22 PE PE2017001530A patent/PE20171624A1/es unknown
- 2011-03-22 AP AP2013006767A patent/AP3699A/en active
-
2013
- 2013-02-07 ZA ZA2013/01042A patent/ZA201301042B/en unknown
- 2013-02-26 CO CO13038918A patent/CO6680669A2/es not_active Application Discontinuation
- 2013-03-14 IL IL225221A patent/IL225221A0/en unknown
- 2013-03-18 CL CL2013000727A patent/CL2013000727A1/es unknown
- 2013-04-04 MA MA35795A patent/MA34593B1/fr unknown
- 2013-04-17 CR CR20130172A patent/CR20130172A/es unknown
- 2013-04-18 EC ECSP13012560 patent/ECSP13012560A/es unknown
-
2016
- 2016-01-18 JP JP2016006833A patent/JP2016074732A/ja not_active Withdrawn
-
2017
- 2017-04-10 JP JP2017077366A patent/JP6475280B2/ja active Active
-
2018
- 2018-09-18 JP JP2018173758A patent/JP2019014726A/ja not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009132123A1 (fr) * | 2008-04-23 | 2009-10-29 | Gilead Sciences, Inc. | Analogues de carba-nucléoside pour un traitement antiviral |
| KR20120102605A (ko) * | 2009-09-21 | 2012-09-18 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 치료용 ２'―플루오로 치환된 카바-뉴클레오사이드 유사체 |
| KR101818779B1 (ko) * | 2009-09-21 | 2018-01-15 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 치료용 ２'―플루오로 치환된 카바-뉴클레오사이드 유사체 |
Also Published As
| Publication number | Publication date |
|---|---|
| PE20171624A1 (es) | 2017-11-02 |
| CA2807496C (fr) | 2019-01-22 |
| IL225221A0 (en) | 2013-06-27 |
| ECSP13012560A (es) | 2013-06-28 |
| EA026523B1 (ru) | 2017-04-28 |
| JP6475280B2 (ja) | 2019-02-27 |
| CA2807496A1 (fr) | 2012-03-29 |
| ZA201301042B (en) | 2014-07-30 |
| AU2011306066B2 (en) | 2015-01-29 |
| SG188223A1 (en) | 2013-04-30 |
| KR20130110168A (ko) | 2013-10-08 |
| CR20130172A (es) | 2013-05-29 |
| AU2011306066A1 (en) | 2013-02-28 |
| JP2013538230A (ja) | 2013-10-10 |
| MX2013003179A (es) | 2013-04-24 |
| AP2013006767A0 (en) | 2013-03-31 |
| CN103108876A (zh) | 2013-05-15 |
| AP3699A (en) | 2016-05-31 |
| WO2012039791A1 (fr) | 2012-03-29 |
| PE20230684A1 (es) | 2023-04-21 |
| CO6680669A2 (es) | 2013-05-31 |
| PE20131165A1 (es) | 2013-10-14 |
| JP2016074732A (ja) | 2016-05-12 |
| BR112013008017A2 (pt) | 2016-06-14 |
| EA201390141A1 (ru) | 2013-09-30 |
| NZ608070A (en) | 2015-11-27 |
| EP2619206A1 (fr) | 2013-07-31 |
| CL2013000727A1 (es) | 2013-08-23 |
| JP2017119726A (ja) | 2017-07-06 |
| JP2019014726A (ja) | 2019-01-31 |
| MA34593B1 (fr) | 2013-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020202600B2 (en) | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment | |
| KR101879887B1 (ko) | 항바이러스 치료용 2'-플루오로 치환된 카바-누클레오시드 유사체 | |
| US8455451B2 (en) | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | |
| US7973013B2 (en) | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | |
| OA16347A (en) | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment. | |
| OA16370A (en) | Mass transfert column. | |
| EA046452B1 (ru) | 2'-фторзамещенные карбануклеозидные аналоги для противовирусного лечения | |
| OA16229A (en) | 2'-Fluoro substituted carba-nucleoside analogs for antiviral treatment. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |